me 2303 has been researched along with Leukemia P388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukatsu, S; Komuro, K; Kunimoto, S; Nosaka, C; Takeuchi, T; Tsuchiya, T | 1 |
| Sudo, Y; Sugimoto, Y; Takamori, R; Tsuruo, T; Yusa, K | 1 |
2 other study(ies) available for me 2303 and Leukemia P388
| Article | Year |
|---|---|
Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites.
Topics: Animals; DNA; Doxorubicin; Esterases; Female; Fluorine; Humans; Hydrolysis; Leukemia L1210; Leukemia P388; Lymphoma, Non-Hodgkin; Mice; Molecular Structure; RNA; Tumor Cells, Cultured | 1990 |
A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Topics: Animals; Doxorubicin; Drug Resistance; In Vitro Techniques; Leukemia L1210; Leukemia P388; Lung Neoplasms; Melanoma, Experimental; Mice; Neoplasms, Experimental; Sarcoma, Experimental; Tumor Cells, Cultured | 1989 |